Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charu Aggarwal

Showing results (11-20 of 198) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2023
Targeting KRAS-Mutated NSCLC: Novel TKIs and BeyondDavid J Cantor, Charu Aggarwal
Current Oncology Reports|May 10, 2018
Combination Immunotherapy in Non-small Cell Lung CancerMelina E Marmarelis, Charu Aggarwal
JCO Oncology Practice|August 12, 2020
Reply to A. Greenberg et alAditi P Singh, Charu Aggarwal
JAMA Oncology|April 13, 2023
Molecular Marker Testing in Curable Non-Small Cell Lung Cancer-Practice Necessarily Precedes DataCharu Aggarwal, Howard Jack West
Current Opinion in Oncology|February 9, 2012
Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancerCharu Aggarwal, Corey J Langer
The Oncologist|December 10, 2020
Adjuvant Osimertinib: A New Standard of CareMichael J Jelinek, Charu Aggarwal
JAMA Network Open|January 22, 2024
Concurrent Circulating Tumor DNA and Tissue Genotyping-Ready for Prime Time?Benjamin A Bleiberg, Charu Aggarwal
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2023
Zipalertinib in <i>EGFR</i> Exon 20-Mutant Non-Small-Cell Lung Cancer: Drug Development in a Rare but Crowded SettingCharu Aggarwal, Stephen V Liu
Journal for Immunotherapy of Cancer|January 19, 2023
Next-generation ctDNA-driven clinical trials in precision immuno-oncologyCharu Aggarwal, Natasha B Leighl
Cancer|January 17, 2020
Systemic therapy for elderly patients with non-small cell lung cancer: Where do we stand in 2019?Charu Aggarwal, Corey J Langer
Pageof 20

Showing results (11-20 of 198) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2023
Targeting KRAS-Mutated NSCLC: Novel TKIs and BeyondDavid J Cantor, Charu Aggarwal
Current Oncology Reports|May 10, 2018
Combination Immunotherapy in Non-small Cell Lung CancerMelina E Marmarelis, Charu Aggarwal
JCO Oncology Practice|August 12, 2020
Reply to A. Greenberg et alAditi P Singh, Charu Aggarwal
JAMA Oncology|April 13, 2023
Molecular Marker Testing in Curable Non-Small Cell Lung Cancer-Practice Necessarily Precedes DataCharu Aggarwal, Howard Jack West
Current Opinion in Oncology|February 9, 2012
Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancerCharu Aggarwal, Corey J Langer
The Oncologist|December 10, 2020
Adjuvant Osimertinib: A New Standard of CareMichael J Jelinek, Charu Aggarwal
JAMA Network Open|January 22, 2024
Concurrent Circulating Tumor DNA and Tissue Genotyping-Ready for Prime Time?Benjamin A Bleiberg, Charu Aggarwal
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2023
Zipalertinib in <i>EGFR</i> Exon 20-Mutant Non-Small-Cell Lung Cancer: Drug Development in a Rare but Crowded SettingCharu Aggarwal, Stephen V Liu
Journal for Immunotherapy of Cancer|January 19, 2023
Next-generation ctDNA-driven clinical trials in precision immuno-oncologyCharu Aggarwal, Natasha B Leighl
Cancer|January 17, 2020
Systemic therapy for elderly patients with non-small cell lung cancer: Where do we stand in 2019?Charu Aggarwal, Corey J Langer
Pageof 20